1075214-55-9
Chemical Structure
ANG1005
Synonym(s): GRN1005; Paclitaxel trevatide
- CAS No.: 1075214-55-9
- Formula:C257H308N32O79
- Molecular Weight:5109.36
IUPAC Name: (4aR,4bS,6aS,8S,9aS,9bS,9cS,10aS,10bR,Z)-7-(1-((R)-4,5-dimethyl-6-oxo-3,6-dihydro-2H-pyran-2-yl)ethylidene)-10b-hydroxy-4a,6a-dimethyl-4-oxo-4,4a,4b,5,6,6a,7,8,9,9a,9b,9c,10a,10b-tetradecahydro-1H-cyclopenta[1,2]phenanthro[9,10-b]oxiren-8-yl acetate
SMILES: O=C([C@@H](NC(CCC(O[C@H]([C@H](C1=CC=CC=C1)NC(C2=CC=CC=C2)=O)C(O[C@@H]3C(C)=C([C@H](C([C@]4(C)[C@H](C[C@@]([H])(OC5)[C@]5(OC(C)=O)[C@]4([C@@H]([C@@]6(C3)O)OC(C7=CC=CC=C7)=O)[H])O)=O)OC(C)=O)C6(C)C)=O)=O)=O)[C@@H](C)O)N[C@H](C(N[C@H](C(N[C@H](C(NCC(NCC(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(O)=O)CC8=CC=C(O)C=C8)=O)CCC(O)=O)=O)CCC(O)=O)=O)[C@@H](C)O)=O)CCCCNC(CCC(O[C@H]([C@H](C9=CC=CC=C9)NC(C%10=CC=CC=C%10)=O)C(O[C@@H]%11C(C)=C([C@H](C([C@]%12(C)[C@H](C[C@@]([H])(OC%13)[C@]%13(OC(C)=O)[C@]%12([C@@H]([C@@]%14(C%11)O)OC(C%15=CC=CC=C%15)=O)[H])O)=O)OC(C)=O)C%14(C)C)=O)=O)=O)=O)CC%16=CC=CC=C%16)=O)CC(N)=O)=O)CC(N)=O)=O)CCCNC(N)=N)=O)CCCCNC(CCC(O[C@H]([C@H](C%17=CC=CC=C%17)NC(C%18=CC=CC=C%18)=O)C(O[C@@H]%19C(C)=C([C@H](C([C@]%20(C)[C@H](C[C@@]([H])(OC%21)[C@]%21(OC(C)=O)[C@]%20([C@@H]([C@@]%22(C%19)O)OC(C%23=CC=CC=C%23)=O)[H])O)=O)OC(C)=O)C%22(C)C)=O)=O)=O)=O)=O)CCCNC(N)=N)=O)CO)=O)=O)=O)CC%24=CC=C(O)C=C%24)=O)CC%25=CC=CC=C%25)=O)CC%26=CC=CC=C%26
Biological Activity: ANG1005 (Paclitaxel trevatide) is a brain-penetrating peptide-drug conjugate. ANG1005, a taxane derivative, consists of three paclitaxel (HY-B0015) molecules covalently linked to Angiopep-2, designed to cross the blood-brain and blood-cerebrospinal barriers and to penetrate malignant cells via low density lipoprotein receptor-related protein (LRP1) transport system[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
ANG1005 | 98.83% | ANG1005 (Paclitaxel trevatide) is a brain-penetrating peptide-drug conjugate. ANG1005, a taxane derivative, consists of three paclitaxel (HY-B0015) molecules covalently linked to Angiopep-2, designed to cross the blood-brain and blood-cerebrospinal barriers and to penetrate malignant cells via low density lipoprotein receptor-related protein (LRP1) transport system. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Thomas FC, et al. Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer. Pharm Res. 2009 Nov;26(11):2486-94. [Content Brief]
- [2]. Li F, et al. Targeting metastatic breast cancer with ANG1005, a novel peptide-paclitaxel conjugate that crosses the blood-brain-barrier (BBB). Genes Dis. 2017 Feb 10;4(1):1-3. [Content Brief]
- [3]. Kumthekar P, et al. ANG1005, a Brain-Penetrating Peptide-Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases. Clin Cancer Res. 2020 Jun 15;26(12):2789-2799. [Content Brief]
Keywords